Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis

Functional defect in regulatory T cells in myasthenia gravis

(2012) Muthusamy Thiruppathi et al.   Annals of the New York Academy of Sciences

Interleukin-21 (IL-21) synergizes with IL-2 to enhance T-cell receptor-induced human T-cell proliferation and counteracts IL-2/transforming growth factor-β-induced regulatory T-cell development

(2012) Alessandra Battaglia et al.   IMMUNOLOGY

Long-lasting treatment effect of rituximab in MuSK myasthenia

(2012) J. Diaz-Manera et al.   NEUROLOGY

Response of patients with refractory myasthenia gravis to rituximab: a retrospective study

(2011) Richard J. Nowak et al.   Therapeutic Advances in Neurological Disorders

Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease

(2010) Arezou Khosroshahi et al.   ARTHRITIS AND RHEUMATISM

B-cell targeted therapies in human autoimmune diseases: an updated perspective

(2010) Michael J. Townsend et al.   IMMUNOLOGICAL REVIEWS

Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity

(2009) Matthew N Meriggioli et al.   LANCET NEUROLOGY

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

(2008) R. Stasi et al.   BLOOD